Published: July 2007

131 pages; Can be printed; fully searchable PDF format; TOC hyperlinks and Internet hyperlinks

 

SKU: TPR3168

 

Price:

$2,595.00 (US Dollars) PDF Single User License

$3,995.00 (US Dollars) PDF Single Office License (2 to 5 users) 

$5,195.00 (US Dollars) PDF Site License

 

Description

 

This report assesses the RNA interference market for drug R&D. RNA interference (RNAi) has been hailed in the science media as the hottest technical breakthrough in bioscience in the last ten years.  A 2006 Nobel Prize was awarded to the two scientists that discovered this important biological effect.

 

RNAi allows scientists to disrupt or silence the expression of a gene being studied. RNAi can also be used as a therapeutic agent. This field has quickly emerged as a fast growing young market.  The report provides the WW outlook and market trends.

 

This must-have report discusses how an expanding number of companies have created a vibrant commercial market that has segmented into different areas of life science research and drug R&D. The market might be worth billions in a few years.

 

This study reviews the market landscape and analyzes the players.  The market areas studied range from life science research products and services to therapeutics or drug delivery tools for RNAi agents.

 

The report discusses RNAi topics including dsRNA, shRNA, siRNA, ddRNA, miRNA, RNAi-as-drug, and targeted disease areas. This study analyzes RNAi deals including M&As, alliances and examples of patent considerations.  For example, a number of big pharma companies are developing drugs with RNAi and have either licensed or partnered with RNAi R&D companies. One big pharma acquired a leading RNAi developer.

 

This report is designed for people that include marketers, business development, top executives, investors, VCs, consultants, R&D managers, entrepreneurs and etc.  The report includes 39 detailed tables and figures that provide key data about items such as strategic alliances, M&As, market size, segments and so on. 

 

Twenty company profiles provide the reader a snapshot of the companies’ focus or activities.  This PDF formatted report is searchable by using key words. Internet links help readers access companies’ own web sites for further review. 

 

Table of Contents

 

1.RNAi Market & Business Models

   Overview of RNA Interference

     Double Stranded RNA (dsRNA)

     Small interfering RNA (siRNA)

     Short Hairpin RNA (shRNA)

     DNA-directed RNAi (ddRNAi)

     MicroRNA (miRNA)

   The RNAi Market & Key Customer Applications

     The WW RNAi Market

     RNAi Tools for Research, Drug Discovery &

          Development

         As Tools for Basic Research

         As Tools for Drug Discovery

         As Tools for Drug Development

     RNAi-as-Drugs (Therapeutics)

   Competitive Market

     Market Map of Major Players

     Major Players by Focus Segment and Product Strategy

     Research Findings  & Analysis

         Market Leaders

         RNAi Moves Upstream on the Drug R&D Path

         Technology Big Picture

         Business Model & Product Development Strategies

2.M&A and Alliance Activities

   Analysis of RNAi M&As and Alliances, 2005 to July-2007

   RNAi Alliances and M&As, 2005 to June-2007

   Intellectual Property and Regulatory Approval

     Intellectual Property

     Regulatory Approval

   Findings: Companies to Watch for Future R&D

     RNAi Technology Companies on the Move

     Big Pharma is Involved in RNAi

3.Market Forecast and Trends

   The WW RNA Interference (RNAi) Market Size 2006-2011

   WW RNAi Market by Segments

     RNAi Market By WW Regions

     RNAi Market By Application Segments

         RNAi in Basic Research

         RNAi in Drug Discovery

         RNAi in Drug Development

         RNAi Therapeutics

     RNAi Application Segment Market Shares, 2007 & 2011

     RNAi Market By Major Disease Segments

         Cancer

         Infections

         Metabolic

         Eye disease

         CNS

         Respiratory

         Inflammation

         Bone Diseases

         Blood Disease

         Cardiovascular

         Diagnostics, Skin Conditions and Others

     Major Disease Segment Market Shares (%), 2007 &

          2011

     RNAi Market By Product Segments

         RNAi Reagents & Related Services

         RNAi Delivery Tools & Devices

         Assay Systems

         Cell Lines & Related

         Discovery Techs, Services & Drugs

         Genomewide RNAi HT/ HC Screening Tools

     RNAi Product Segment Market Shares (%), 2007 & 2011

   Key Trends/ Future Directions

     Big Pharma Starting to Get Involved in RNAi

     Advances Made in Dealing With Off-target Effects

     Growing Knowledge About microRNAs

     Direct Delivery of RNAi-based Drugs

     Systemic Delivery of RNAi Drugs

     RNAi Future Direction Timeline

4.Selected Companies Working in RNAi

   Alnylam Pharmaceuticals, Inc.

   Ambion, Inc.

   Avalon Pharmaceuticals, Inc.

   Benitec, Ltd.

   Cenix Bioscience GmbH

   CytRx Corporation

   Dharmacon, Inc.

   Integrated DNA Technologies, Inc. (IDT)

   Intradigm Corporation

   Intronn, Inc.

   Invitrogen Corporation

   Lentigen Corporation

   Mirus Bio Corporation

   Nastech Pharmaceutical Company Inc.

   Open Biosystems

   Opko Health, Inc.

   Panomics, Inc.

   RNAx GmbH

   Sirna Therapeutics, Inc.

   Targeted Genetics Corporation

5.Findings and Suggestions

   Review of Findings and Key Trends

     RNAi Technology

     Competitive Landscape

     M&As and Alliances

     Patents

     Market Assessment

   Recommendations to Capture Opportunities

   Products Needed by RNAi Users in R&D

   Future Market Prospects

6.Appendix

   RNAi Glossary

   Company Contacts

   About Takeda Pacific

   About the Authors

                                                            

List of Tables

 

Table 1. Diseases Targeted by Direct Delivery of RNAi Drugs

Table 2. Diseases Targeted by Systemic Delivery of RNAi Drugs

Table 3. Major Players in the RNAi Market

Table 4. Major Players by Focus Segment and Product Strategy

Table 5. Summary of RNAi M&As and Alliances, 2005 to July-2007

Table 6. M&As and Alliances, Jan-July/ 2007

Table 7. M&As and Alliances, 2006

Table 8. M&As and Alliances, 2005

Table 9. RNAi Related Patent Applications (US), 2002-1H2007

Table 10. Key Patents for RNAi Reagents and Drugs

Table 11. RNAi Therapeutics In /(or Near) Clinical Trials

Table 12. Top RNAi Alliance Players: RNAi Technology Companies

Table 13. Top RNAi Alliance Players: Big Pharmas

Table 14. WW RNAi Market Size By Total Revenues ($M), 2006-2011

Table 15. WW RNAi Market By WW Regions and Revenues, 2006-2011

Table 16. WW Regions Market Shares (%), 2007 & 2011

Table 17. US RNAi Market By Application Segment Revenues ($M), 2006-2011

Table 18. Application Segment Market Shares (%), 2007 & 2011

Table 19. RNAi Market By Major Disease Segments, Revenues ($M), 2006-2011

Table 20. Major Disease Segment Market Shares (%), 2007 & 2011

Table 21. RNAi Market By Product Segments, Revenues ($M), 2006-2011

Table 22. Product Segment Market Shares (%), 2007 & 2011

Table 23. RNAi R&D Unmet Needs - Selected Opportunity Matrix

 

 

List of Figures

 

Figure 1. Timeline for Key RNAi Technology Developments

Figure 2. Central Theme of Modern Biology, DNA encodes for Proteins

Figure 3. The RNAi Process with dsRNA, shRNA, siRNA and RISC

Figure 4. RNAi R&D Market by Major Applications

Figure 5. RNAi Related Patent Applications (US), 2002-1H2007

Figure 6. New Drug Approval Timeline and Roadmap

Figure 7. WW RNAi Market Size By Total Revenues ($M), 2006-2011

Figure 8. WW RNAi Market By WW Regions and Revenues, 2006-2011

Figure 9.  WW RNAi Market By WW Regions and Shares, 2007 & 2011

Figure 10. WW RNAi Market By Application Segment Revenues,        2006-2011

Figure 11. RNAi Application Segment Market Shares (%), 2007 & 2011

Figure 12. RNAi Market By Major Disease Segments, Revenues ($M),

                2006-2011

Figure 13. Major Disease Segment Market Shares (%), 2007 & 2011

Figure 14. RNAi Market By Product Segments, Revenues ($M), 2006-2011

Figure 15. Product Segment Market Shares (%), 2007 & 2011

Figure 16. RNAi Future Direction Timeline to 2011